Table 2 Baseline characteristics at antiretroviral treatment (ART) initiation of 2170 children.
Site | N | Girl (%) | Median Age (years) (IQR) | %AIDS or clinical stage IV (%Missing) | Initial ART regimen (%) | Median CD4 cell count (IQR) | Median CD4 percent (IQR) | %Immuno-supression* (%Missing) | %CTX Status$ (%Missing) | Year of ART initiation | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2NRTI+1NNRTI | 2NRTI +1 PI | Others | ≤ 2004 | 2005 | ≥ 2006 | |||||||||
UPEIV | 71 | 46.5 | 4 (2-7) | 24.3 (1.4) | 0.0 | 100.0 | 0.0 | 291 (132-517) | 8(5-12) | 89.9 (2.8) | 100.0 (1.4) | 50.7 | 19.7 | 29.6 |
CEPREF | 306 | 42.5 | 6 (3-9) | 20.2 (1.6) | 63.1 | 33.3 | 3.6 | 356 (106-728) | 11 (6-16) | 79.5 (15.4) | 32.8 (0.3) | 12.7 | 50.7 | 36.6 |
MTCT Plus | 74 | 52.7 | 2 (1-4) | 10.3 (21.6) | 35.1 | 64.9 | 0.0 | 858 (437-1285) | 18 (14-24) | 57.7 (4.1) | 89.7 (21.6) | 41.9 | 23.0 | 35.1 |
CHU Yopougon | 650 | 48.3 | 6(3-10) | 0.5 (4.0) | 46.0 | 53.5 | 0.5 | 445 (201-738) | 14(7-21) | 60.1 (14.5) | 15.6 (0.6) | 52.3 | 24.2 | 23.5 |
CIRBA | 141 | 47.5 | 4 (2-7) | 53.3 (5.1) | 66.7 | 31.9 | 1.4 | 393 (227-947) | 14 (6-20) | 72.0 (46.8) | 71.2 (48.2) | 13.5 | 19.9 | 66.7 |
FAJARA | 23 | 47.8 | 6 (4-12) | - (100.0) | 82.6 | 13.0 | 4.3 | 305 (220-580) | 15 (9-19) | 50.0 (4.3) | - (100.0) | 4.3 | 34.8 | 60.9 |
KBTH | 128 | 47.7 | 6 (3-8) | 3.9 (0.0) | 96.9 | 0.0 | 3.1 | 332 (77-684) | 11 (4-17) | 65.6 (25.0) | 93.8 (0.0) | 11.7 | 51.6 | 36.7 |
Albert Royer | 104 | 43.3 | 7 (4-10) | 55.3 (1.0) | 81.7 | 15.4 | 2.9 | 340 (31-610) | 9 (4-15) | 63.9 (41.3) | 92.3 (0.0) | 32.7 | 20.2 | 47.1 |
Gabriel Toure | 673 | 40.4 | 4 (2-8) | 30.4 (2.2) | 75.2 | 23.0 | 1.8 | 335 (115-602) | - | 55.8 (16.3) | - (100.0) | 39.8 | 18.0 | 42.2 |
Total | 2170 | 44.8 | 5 (2-9) | 19.1 (13.2) | 62.0 | 36.3 | 1.7 | 385 (142-691) | 13 (7-19) | 63.4 (18.3) | 42.7 (36.2) | 36.0 | 27.1 | 36.9 |